About Heparan sulfate 2-O-sulfotransferase 1
Heparan sulfate 2-O-sulfotransferase 1 (HS2ST1) is a protein
from Homo sapiens identified by UniProt accession
Q7LGA3, 356 residues long.
MolForge cross-references it against 0 known binders and
84 disease associations.
Target properties
| Protein name | Heparan sulfate 2-O-sulfotransferase 1 |
| UniProt accession | Q7LGA3 |
| Gene | HS2ST1 |
| Organism | Homo sapiens |
| Length | 356 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (84)
Diseases linked to this target (Open Targets).
- neurofacioskeletal syndrome with or without renal agenesis · score 0.66
- Intellectual disability · score 0.53
- complex neurodevelopmental disorder · score 0.37
- genetic disorder · score 0.19
- mathematical ability · score 0.13
- cortical surface area measurement · score 0.09
- uveal coloboma-cleft lip and palate-intellectual disability · score 0.04
- spondyloperipheral dysplasia · score 0.04
- Klippel-Feil syndrome 3, autosomal dominant · score 0.04
- Kniest dysplasia · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7LGA3-F1 | alphafold | PREDICTED | 91.73 | — |
Amino-acid sequence (356 residues)
MGLLRIMMPP KLQLLAVVAF AVAMLFLENQ IQKLEESRSK LERAIARHEV REIEQRHTMD GPRQDATLDE EEDMVIIYNR VPKTASTSFT NIAYDLCAKN KYHVLHINTT KNNPVMSLQD QVRFVKNITS WKEMKPGFYH GHVSYLDFAK FGVKKKPIYI NVIRDPIERL VSYYYFLRFG DDYRPGLRRR KQGDKKTFDE CVAEGGSDCA PEKLWLQIPF FCGHSSECWN VGSRWAMDQA KYNLINEYFL VGVTEELEDF IMLLEAALPR FFRGATELYR TGKKSHLRKT TEKKLPTKQT IAKLQQSDIW KMENEFYEFA LEQFQFIRAH AVREKDGDLY ILAQNFFYEK IYPKSN
Explore Heparan sulfate 2-O-sulfotransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets